Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Fr | NextCure nabs NexImmune, Celgene research vet as new CMO 6 months after former CMO quit | ||
Fr | Cambridge Univ. researchers develop DNA test for COVID-19's secondary, hospital-acquired infections | ||
Fr | JPM: Thermo Fisher picks up Novasep's viral vector business for $878M outright | ||
Fr | Landos Biopharma guns for a $100 million IPO to boost AI autoimmune R&D work | ||
Fr | Eli Lilly chips $30M into VC fund aimed at minority-owned healthcare companies | ||
Fr | How a gene linked to the circadian clock could point to new prostate cancer treatments | ||
Fr | Sinopharm claims COVID-19 vaccine safe in kids aged 3 and up | ||
Fr | Parexel, Signify join forces to better diversity in clinical trials | ||
Fr | Ex-Merck scientist accused of stealing trade secrets on Keytruda, raising threat of 10-year prison term | ||
Fr | Chutes & Ladders-Bristol Myers hematology chief Ahmed hits exit | ||
Fr | AI cancer pathology developer Paige nets $100M in venture capital funding | ||
Do | Philips joins Merck KGaA to develop AI-guided fertility treatments | ||
Do | JPM: Can we take J.P. Morgan out of San Francisco? We're virtually there | ||
Do | Eye stem cell transplant to treat blindness bolsters retinal function in monkeys | ||
Do | Meet Binney Street Capital: Dana-Farber Cancer Institute's first venture fund | ||
Do | Knopp's oral asthma drug hits primary endpoint in phase 2 | ||
Do | NewAmsterdam bags $196M to resurrect Amgen's discarded CETP drug | ||
Do | Secretive Sana, still a year away from the clinic, files for an IPO after a mammoth raise | ||
Mi | JPM: Alector, Annexon, Athira on what an aducanumab approval could mean for Alzheimer's R&D | ||
Mi | Cognito Therapeutics nets FDA breakthrough label for light, sound therapy for Alzheimer's disease | ||
Mi | JPM: Imara CEO Ballal on fighting sickle cell disease during COVID-19 | ||
Mi | JPM, Day 3: CureVac partner Bayer says not to discount its vaccine efforts, CROs better prepped for new wave and more | ||
Mi | JPM: Aridis CEO Truong on why the pandemic hasn't bolstered antibiotics R&D and what needs to change | ||
Mi | JPM: CureVac's new pharma partner Bayer says its COVID-19 vaccine not just an also-ran | ||
Mi | A COVID-19 treatment candidate that fuses tiny antibodies from llamas and alpacas shows promise |